Rakovina Therapeutics Inc
- LAST PRICE0.0800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0750/ 20
- Ask / Lots0.0800/ 38
- Open / Previous Close0.0800 / 0.0800
- Day Range
- 52 Week Range
- Volume12,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RKV |
|---|---|---|
| 09:35 ET | 5000 | 0.08 |
| 10:27 ET | 5000 | 0.075 |
| 03:21 ET | 1000 | 0.08 |
| 04:00 ET | 1000 | 0.08 |
Oct 25, 2024
Oct 23, 2024
Rakovina Therapeutics Announces Initial Drug Candidates from Deep Docking AI Molecule Discovery Platform, from 7:30AM ET on Wednesday Oct 23, 2024 by Dow Jones
7:30AM ET on Wednesday Oct 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Rakovina Therapeutics Inc | 7.2M | -1.9x | --- |
Glow Lifetech Corp | 7.3M | -1.6x | --- |
XORTX Therapeutics Inc | 5.6M | -2.9x | --- |
Marvel Biosciences Corp | 5.8M | -2.5x | --- |
Hemostemix Inc | 8.7M | -4.2x | --- |
Asep Medical Holdings Inc | 5.2M | -0.9x | --- |
Company Information
Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. The Company is focused on the development of new cancer treatments based on novel deoxyribonucleic acid (DNA)-damage response technologies. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase (HDAC) in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.
Contact Information
- Headquarters
- 105 - 1008 Beach AvenueVancouver, BC, Canada V6E 1T7
- Phone
- 604-619-0225
- Fax
- 604-980-6264
Executives
- Executive Chairman of the Board
- Jeffrey Bacha
- President, Chief Scientific Officer
- Mads Daugaard
- Independent Non-Executive Vice Chairman of the Board
- Alfredo De Lucrezia
- Chief Financial Officer
- David Hyman
- Chief Operating Officer
- John Langlands
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 90.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.01 |
EPS | $-0.04 |
Book Value | $0.05 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
